Powered by
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup that’s about to introduce a new class of cholesterol-fighting drugs, reported a loss of $54.2 million or $2.01 a share …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging to consumers for the pharmaceutical industry, reported net income of $406,617 or 3 cents a share, up 45 percent in …
GRAND RAPIDS—Tetra Discovery Partners, a clinical-stage biotechnology company, announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research …
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
ANN ARBOR—Officials at Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), a pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced a $200 million funding agreement with an investor group …
ROCHESTER—Officials of OptimizeRx Corp. (Nasdaq: OPRX), the provider of digital marketing messaging for the pharmaceutical industry, said the company is expected to join the Russell Microcap and Russell 3000 stock …
(Updated June 5 with stock price) ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging for the pharmaceutical industry, reported net income of $6,529 in the first quarter ended March 31, vs. a loss of …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
ANN ARBOR—An Ann Arbor company that has developed a system to screen cancer patients to precision-designed treatments that will be most effective for them has a new clinical development collaboration …